Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 7,828 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Virus Infection, RNA Clear all
Completed No phase listed Observational Accepts healthy volunteers

A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth

NCT00069004
View directory record Official record
Conditions
HIV Infections, HIV-Associated Lipodystrophy Syndrome, HIV Lipodystrophy Syndrome, Lipodystrophy, Dyslipidemia, Osteoporosis, Osteopenia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 25 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
36
States / cities
Birmingham, Alabama • Alhambra, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 19, 2026, 7:17 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparative Autoantibody and Immunologic Cell Marker Study

NCT02422875
View directory record Official record
Conditions
Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 7:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C

NCT02123212
View directory record Official record
Conditions
Hepatitis C, Chronic Hepatitis C
Interventions
Mailer, In-person recruitment, EHR Alert
Other
Lead sponsor
National Opinion Research Center
Other
Eligibility
47 Years to 69 Years
Enrollment
29,607 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
Birmingham, Alabama • Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 19, 2026, 7:17 AM EDT
Terminated Phase 1 Interventional

HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity

NCT01377909
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
statin
Drug
Lead sponsor
Bader, Ted, M.D.
Individual
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 19, 2026, 7:17 AM EDT
Completed Not applicable Interventional

Electronic Record Assimilation and Subsequent Eradication of Hepatitis C

NCT04873609
View directory record Official record
Conditions
Hepatitis C, Liver Diseases
Interventions
Patient portal message
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
54 Years to 74 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 19, 2026, 7:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ACTIVATE in Public Housing

NCT06075732
View directory record Official record
Conditions
Pneumonia, Influenza, Varicella Zoster, Meningitis, COVID-19, Vaccine Hesitancy
Interventions
Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 19, 2026, 7:17 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety and Efficacy of Baricitinib for COVID-19

NCT04340232
View directory record Official record
Conditions
COVID-19
Interventions
Baricitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 19, 2026, 7:17 AM EDT
Terminated Phase 2 Interventional

BreathID Multi-center HCV Liver Breath Test Study

NCT00350714
View directory record Official record
Conditions
Hepatitis C
Interventions
MBT and BreathID
Other
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
New York, New York • Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 19, 2026, 7:17 AM EDT
Completed Phase 1 Interventional Results available

An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)

NCT03157167
View directory record Official record
Conditions
Kaposi Sarcoma, HIV Infections
Interventions
Tc99m-tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 19, 2026, 7:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.

NCT01277692
View directory record Official record
Conditions
Hepatitis C
Interventions
GSK2336805 10mg, GSK2336805 30mg, GSK2236805 100mg, GSK2236805 200mg, GSK2236805 10mg, GSK2236805 dose to be determined up to 100mg, GSK2236805 5mg, GSK2236805 30mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Chula Vista, California • Lenexa, Kansas • Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 19, 2026, 7:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk Assessment of Long-Haul Truck Drivers

NCT00381992
View directory record Official record
Conditions
Gonorrhea, Chlamydia Infections, Hepatitis B, Hepatitis C, Diabetes Mellitus, Hypertension, Obesity, HIV Infections, Hyperlipidemia
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 19, 2026, 7:17 AM EDT
Completed Phase 2 Interventional

A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3

NCT00000771
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Paromomycin sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
14
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 19, 2026, 7:17 AM EDT
Completed Not applicable Interventional

A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women

NCT00000744
View directory record Official record
Conditions
Candidiasis, Candidiasis, Esophageal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • Wilmington, Delaware + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 19, 2026, 7:17 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors

NCT05164744
View directory record Official record
Conditions
COVID-19 Pneumonia, COVID-19, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Lower Respiratory Infection, COVID-19 Acute Bronchitis, Coronavirus Disease 2019
Interventions
Cardiac MRI, Echocardiogram, 6-minute walk test, Questionnaire
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 19, 2026, 7:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Investigating Severe Acute Respiratory Syndrome (SARS)

NCT00066209
View directory record Official record
Conditions
SARS Virus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 7:17 AM EDT
Completed Not applicable Interventional

Healthy Choices to Promote Health and Reduce Risk in HIV-Infected Youth

NCT00103532
View directory record Official record
Conditions
HIV Infection
Interventions
Healthy Choices - Motivational Enhancement Intervention, Standard care
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
6
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 19, 2026, 7:17 AM EDT
Completed Not applicable Interventional Results available

Lottery Incentive Nudges to Increase Influenza Vaccinations

NCT05012163
View directory record Official record
Conditions
Influenza, Vaccination, Health Promotion, Health Behavior
Interventions
Reminder, Financial incentive, Lottery
Behavioral
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
57,581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 19, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors

NCT00497081
View directory record Official record
Conditions
Substance Abuse, HIV Infections
Interventions
mirtazapine, placebo
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 60 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 19, 2026, 7:17 AM EDT
Completed Phase 3 Interventional

HIV Symptom Management Program for African American Mothers

NCT00065819
View directory record Official record
Conditions
HIV Infections
Interventions
HIV Symptom Education Program
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
0 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 7:17 AM EDT
Completed No phase listed Observational

COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications

NCT04535128
View directory record Official record
Conditions
Covid19, Thrombosis Embolism, DVT, Pulmonary Embolism, Myocardial Infarction, Stroke
Interventions
No intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
11,000 participants
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 19, 2026, 7:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

NCT00146328
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
86
States / cities
Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 56 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 19, 2026, 7:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults

NCT02317900
View directory record Official record
Conditions
Dengue
Interventions
TV005, Placebo, rDEN2∆30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 19, 2026, 7:17 AM EDT
Terminated Phase 2 Interventional Results available

Nebulized Heparin for COVID19-associated Acute Respiratory Failure

NCT04842292
View directory record Official record
Conditions
Covid19
Interventions
Heparin, Placebo
Drug
Lead sponsor
Brittany Bissell
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 19, 2026, 7:17 AM EDT